Pexelizumab
Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting[1] and angioplasty,[2][3] among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.[4]
Current Status
Alexion, the developer of pexelizumab stopped development due to disappointing phase 3 results indicating the heart-attack drug is no better than placebo.[5]
References
- ↑ ClinicalTrials.gov: Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass
- ↑ ClinicalTrials.gov: Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction
- ↑ Testa, L; Van Gaal, WJ; Bhindi, R; Biondi-Zoccai, GG; Abbate, A; Agostoni, P; Porto, I; Andreotti, F et al. (2008). "Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients". The Journal of thoracic and cardiovascular surgery 136 (4): 884–93. doi:10.1016/j.jtcvs.2007.12.062. PMID 18954626.
- ↑ Mathew, JP; Shernan, SK; White, WD; Fitch, JC; Chen, JC; Bell, L; Newman, MF (2004). "Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery.". Stroke; a journal of cerebral circulation 35 (10): 2335–9. doi:10.1161/01.STR.0000141938.00524.83. PMID 15331798.
- ↑ Analysis: Alexion's pexelizumab fails
|
---|
| Intracellular (initiation) | |
---|
| Intracellular (reception) | |
---|
| Extracellular | |
---|
| |
---|
| Description |
- Physiology
- cells
- autoantigens
- autoantibodies
- complement
- surface antigens
- IG receptors
|
---|
| Disease |
- Allergies
- Immunodeficiency
- Immunoproliferative immunoglobulin disorders
- Hypersensitivity and autoimmune disorders
- Neoplasms and cancer
|
---|
| Treatment |
- Procedures
- Drugs
- antihistamines
- immunostimulants
- immunosuppressants
- monoclonal antibodies
|
---|
|
|
|
---|
| Immune system ("-l(i[m])-") | Human ("-limu-") | |
---|
| Mouse ("-limo-") | |
---|
| Chimeric ("-lixi-") | |
---|
| Humanized ("-lizu-") | |
---|
| Chimeric + humanized ("-lixizu-") | |
---|
|
---|
| Interleukin ("-k(i[n])-") | Human ("-kinu-") | |
---|
| Humanized ("-kizu-", "-kinzu-") | |
---|
|
---|
| Inflammatory lesions ("-les-") | |
---|
| |
---|
| Description |
- Physiology
- cells
- autoantigens
- autoantibodies
- complement
- surface antigens
- IG receptors
|
---|
| Disease |
- Allergies
- Immunodeficiency
- Immunoproliferative immunoglobulin disorders
- Hypersensitivity and autoimmune disorders
- Neoplasms and cancer
|
---|
| Treatment |
- Procedures
- Drugs
- antihistamines
- immunostimulants
- immunosuppressants
- monoclonal antibodies
|
---|
|
|